Evidence map›Paper›PMID 30984133›Full record

ArticleFrontiers in microbiology2019

Type II Restriction of Bacteriophage DNA With 5hmdU-Derived Base Modifications.

Kiersten Flodman, Rebecca Tsai, Michael Y Xu, Ivan R Corrêa, Alyssa Copelas, Yan-Jiun Lee, Ming-Qun Xu, Peter Weigele, Shuang-Yong Xu

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Genetic engineering ofMicrobial genomics · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Viruses · 2025
    Article
  7. Complete genome sequences ofmicroPublication biology · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Pathways of thymidine hypermodification.Nucleic acids research · 2022
    Article
  17. Article
  18. Review
  19. Article
  20. Characterization of BisI Homologs.Frontiers in microbiology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Kiersten FlodmanNew England Biolabs, Inc., Ipswich, MA, United States.
Rebecca TsaiNew England Biolabs, Inc., Ipswich, MA, United States.
Michael Y XuNew England Biolabs, Inc., Ipswich, MA, United States.
Ivan R CorrêaNew England Biolabs, Inc., Ipswich, MA, United States.
Alyssa CopelasNew England Biolabs, Inc., Ipswich, MA, United States.
Yan-Jiun LeeNew England Biolabs, Inc., Ipswich, MA, United States.
Ming-Qun XuNew England Biolabs, Inc., Ipswich, MA, United States.
Peter WeigeleNew England Biolabs, Inc., Ipswich, MA, United States.
Shuang-Yong XuNew England Biolabs, Inc., Ipswich, MA, United States.
New England Biolabs (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To counteract bacterial defense systems, bacteriophages (phages) make extensive base modifications (substitutions) to block endonuclease restriction. Here we evaluated Type II restriction of three thymidine (T or 5-methyldeoxyuridine, 5mdU) modified phage genomes:

Indexed as

5hmdU-derived nucleotide modificationDelftia phi W-14phage therapyPseudomonas bacteriophage (phage) M6Salmonella phage ViIType II restriction and modification

Identifiers

PMID30984133
PMCPMC6449724
OpenAlexW2932297240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.